Stereotactic radiotherapy with Gamma Master System^® for palliation of hepatocellular carcinoma in patients with liver cirrhosis.

IF 3.3 2区医学 Q2 ONCOLOGY

Radiation Oncology Pub Date : 2025-07-15 DOI:10.1186/s13014-025-02683-y

Bin Qiu, Fang Fang, Peng Zhen, Junjie Wang

{"title":"Stereotactic radiotherapy with Gamma Master System® for palliation of hepatocellular carcinoma in patients with liver cirrhosis.","authors":"Bin Qiu, Fang Fang, Peng Zhen, Junjie Wang","doi":"10.1186/s13014-025-02683-y","DOIUrl":null,"url":null,"abstract":"Background: Stereotactic radiotherapy with Gamma Master System® delivered for portal vein tumor thrombosis (PVTT) located in the main portal vein is previously exploited. The study aimed to evaluate the efficacy and safety of stereotactic radiotherapy with Gamma Master System® for palliation of hepatocellular carcinoma in patients with liver cirrhosis.Methods: From March 2014 to March 2024, 96 patients (mean age, 59.7 ± 9.0, range, 39-87 years; 86, 89.6% males) with hepatocellular carcinoma and liver cirrhosis underwent stereotactic radiotherapy with Gamma Master System® in our institute were retrospectively reviewed.Results: Of the 96 patients, 80 (83.3%) patients demonstrated disease control, defined as 8 (8.3%) complete response, 63 (65.6%) partial response, and 9 (9.4%) stable disease. Median progression-free survival (PFS) was 6.0 ± 0.6 months [interquartile range (IQR), 3-14 months], with a 1-year PFS rate of 26.9%, the median overall survival (OS) reached 14.0 ± 1.3 months (IQR, 8-27 months), with an estimated 1-year survival rate of 61.8%. Of the 61 painful patients, 59 (96.7%) reported pain relief. The AFP decreased from 1070.5 ± 364.4 ng/ml before radiotherapy to 688.6 ± 301.5 ng/ml after radiotherapy (p = 0.081). Child-Pugh classification (A 74 cases, 77.1%, and B 22 cases, 22.6%) before radiotherapy was similar to that (A 74 cases, 77.1%, and B 22 cases, 22.6%) after radiotherapy, with 1 case changed from A to B and 1 case changed from B to A. Only one patient experienced grade 4 hematologic toxicity, which was managed with transfusion. Immune-related dermatitis occurred in 2 (7.1%) of the 28 patients combined with immunotherapy/targeted therapy. No other major complications were observed.Conclusions: Stereotactic radiotherapy with Gamma Master System® for palliation appears effective and safe in liver cirrhosis patients with hepatocellular carcinoma yielding a high rate of tumor response. This treatment may provide a valuable option for pain relief. Further study is warranted.","PeriodicalId":49639,"journal":{"name":"Radiation Oncology","volume":"20 1","pages":"110"},"PeriodicalIF":3.3000,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12265294/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiation Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13014-025-02683-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Stereotactic radiotherapy with Gamma Master System^® delivered for portal vein tumor thrombosis (PVTT) located in the main portal vein is previously exploited. The study aimed to evaluate the efficacy and safety of stereotactic radiotherapy with Gamma Master System^® for palliation of hepatocellular carcinoma in patients with liver cirrhosis.

Methods: From March 2014 to March 2024, 96 patients (mean age, 59.7 ± 9.0, range, 39-87 years; 86, 89.6% males) with hepatocellular carcinoma and liver cirrhosis underwent stereotactic radiotherapy with Gamma Master System^® in our institute were retrospectively reviewed.

Results: Of the 96 patients, 80 (83.3%) patients demonstrated disease control, defined as 8 (8.3%) complete response, 63 (65.6%) partial response, and 9 (9.4%) stable disease. Median progression-free survival (PFS) was 6.0 ± 0.6 months [interquartile range (IQR), 3-14 months], with a 1-year PFS rate of 26.9%, the median overall survival (OS) reached 14.0 ± 1.3 months (IQR, 8-27 months), with an estimated 1-year survival rate of 61.8%. Of the 61 painful patients, 59 (96.7%) reported pain relief. The AFP decreased from 1070.5 ± 364.4 ng/ml before radiotherapy to 688.6 ± 301.5 ng/ml after radiotherapy (p = 0.081). Child-Pugh classification (A 74 cases, 77.1%, and B 22 cases, 22.6%) before radiotherapy was similar to that (A 74 cases, 77.1%, and B 22 cases, 22.6%) after radiotherapy, with 1 case changed from A to B and 1 case changed from B to A. Only one patient experienced grade 4 hematologic toxicity, which was managed with transfusion. Immune-related dermatitis occurred in 2 (7.1%) of the 28 patients combined with immunotherapy/targeted therapy. No other major complications were observed.

Conclusions: Stereotactic radiotherapy with Gamma Master System^® for palliation appears effective and safe in liver cirrhosis patients with hepatocellular carcinoma yielding a high rate of tumor response. This treatment may provide a valuable option for pain relief. Further study is warranted.

Abstract Image

查看原文本刊更多论文

伽玛大师系统®立体定向放疗对肝硬化患者肝细胞癌的缓解作用。

背景：立体定向放疗的伽玛主系统®提供门静脉肿瘤血栓形成（PVTT）位于主要的门静脉以前被开发。本研究旨在评价伽玛大师系统（Gamma Master System®）立体定向放疗对肝硬化肝细胞癌患者的疗效和安全性。方法：2014年3月~ 2024年3月，96例患者(平均年龄59.7±9.0岁，范围39 ~ 87岁；我们回顾性回顾了我院86例（89.6%男性）肝癌和肝硬化患者接受伽玛主系统®立体定向放疗的病例。结果：96例患者中，80例（83.3%）患者表现出疾病控制，定义为8例（8.3%）完全缓解，63例（65.6%）部分缓解，9例（9.4%）疾病稳定。中位无进展生存期（PFS）为6.0±0.6个月[四分位间距（IQR）， 3-14个月]，1年PFS率为26.9%，中位总生存期（OS）为14.0±1.3个月（IQR， 8-27个月），估计1年生存率为61.8%。61例疼痛患者中，59例（96.7%）报告疼痛缓解。AFP由放疗前的1070.5±364.4 ng/ml降至放疗后的688.6±301.5 ng/ml （p = 0.081）。放疗前Child-Pugh分型（A 74例，77.1%，B 22例，22.6%）与放疗后Child-Pugh分型（A 74例，77.1%，B 22例，22.6%）相似，其中A变为B 1例，B变为A 1例，仅有1例出现4级血液学毒性，经输血处理。在28例联合免疫治疗/靶向治疗的患者中，2例（7.1%）发生免疫相关性皮炎。未见其他主要并发症。结论：伽玛大师系统（Gamma Master System®）立体定向放疗对肝硬化合并肝细胞癌患者的缓解有效且安全，肿瘤反应率高。这种治疗可能为缓解疼痛提供了一个有价值的选择。值得进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Radiation Oncology ONCOLOGY-RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

CiteScore

6.50

自引率

2.80%

发文量

181

审稿时长

3-6 weeks

期刊介绍： Radiation Oncology encompasses all aspects of research that impacts on the treatment of cancer using radiation. It publishes findings in molecular and cellular radiation biology, radiation physics, radiation technology, and clinical oncology.